Cannabinoids, opioids and eating behavior: The molecular face of hedonism?

Brain Research Reviews

Volumn 51, Issue 1, 2006, Pages 85-107

  Cota, Daniela ^a   Tschöp, Matthias H ^a   Horvath, Tamas L ^b   Levine, Allen S ^c  

^a UNIVERSITY OF CINCINNATI   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c University of Minnesota   (United States)

Author keywords

Cannabinoid; CB1; Food intake; Hypothalamus; Opioid; Reward

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; NALMEFENE; NALOXONE; NALTREXONE; OPIATE; OPIATE ANTAGONIST; OPIATE RECEPTOR; PLACEBO; RIMONABANT;

ADDICTION; ANATOMY; ASPLENIA; CHEMICAL INTERACTION; CLINICAL TRIAL; COMORBIDITY; DRUG EFFICACY; DYSLIPIDEMIA; ENERGY BALANCE; ENVIRONMENTAL FACTOR; FEEDING BEHAVIOR; FOOD INTAKE; HOMEOSTASIS; HUMAN; HYPOTHALAMUS; LIFE EXPECTANCY; LIFESTYLE; LIVER TOXICITY; MOLECULAR BIOLOGY; NAUSEA; NEUROANATOMY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW;

ANIMALS; CANNABINOIDS; ENDOCANNABINOIDS; ENERGY METABOLISM; FEEDING BEHAVIOR; HUMANS; NARCOTIC ANTAGONISTS; NARCOTICS; OBESITY; RECEPTOR CROSS-TALK; RECEPTORS, CANNABINOID; RECEPTORS, OPIOID;

EID: 33646889517     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2005.10.004     Document Type: Review

References (196)

1. Abel E.L. Cannabis: effects on hunger and thirst. Behav. Biol. 15 (1975) 255-281
2. Allen K.V., McGregor I.S., Hunt G.E., Singh M.E., and Mallet P.E. Regional differences in naloxone modulation of Δ9-THC induced Fos expression in rat brain. Neuropharmacology 44 (2003) 264-274
3. Arbisi P.A., Billington C.J., and Levine A.S. The effect of naltrexone on taste detection and recognition threshold. Appetite 32 (1999) 241-249
4. Azzara A.V., Bodnar R.J., Delamater A.R., and Sclafani A. Naltrexone fails to block the acquisition or expression of a flavor preference conditioned by intragastric carbohydrate infusions. Pharmacol. Biochem. Behav. 67 (2000) 545-557
5. Barton C., York D.A., and Bray G.A. Opioid receptor subtype control of galanin-induced feeding. Peptides 17 (1996) 237-240
6. Beinfeld M.C., and Connolly K. Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids. Neurosci. Lett. 301 (2001) 69-71
7. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., and Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277 (1997) 1094-1097
8. Berger A., Crozier G., Bisogno T., Cavaliere P., Innis S., and Di Marzo V. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6402-6406
9. Berridge K.C. Food reward: brain substrates of wanting and liking. Neurosci. Biobehav. Rev. 20 (1996) 1-25
10. Berthoud H.R. Multiple neural systems controlling food intake and body weight. Neurosci. Biobehav. Rev. 26 (2002) 393-428
11. Bertino M., Beauchamp G.K., and Engelman K. Naltrexone, an opiate blocker, alters taste perception and nutrient intake in humans. Am. J. Physiol. 261 (1991) R59-R63
12. Bisogno T., Berrendero F., Ambrosino G., Cebeira M., Ramos J.A., Fernandez-Ruiz J.J., and Di Marzo V. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun. 256 (1999) 377-380
13. Bisogno T., Melck D., Bobrov M., Gretskaya N.M., Bezuglov V.V., De Petrocellis L., and Di Marzo V. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J. 3 (2000) 817-824
14. Bisogno T., Ligresti A., and Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacol. Biochem. Behav. 81 (2005) 224-238
15. Bodnar R.J., and Klein G.E. Endogenous opiates and behavior: 2003. Peptides 25 (2004) 2205-2256
16. Bojesen I.N., and Hansen H.S. Binding of anandamide to bovine serum albumin. J. Lipid Res. 44 (2003) 1790-1794
17. Breivogel C.S., Griffin G., Di Marzo V., and Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60 (2001) 155-163
18. Brewerton T.D., Lydiard R.B., Laraia M.T., Shook J.E., and Ballenger J.C. CSF beta-endorphin and dynorphin in bulimia nervosa. Am. J. Psychiatry 149 (1992) 1086-1090
19. Brown J.E., Kassouny M., and Cross J.K. Kinetic studies of food intake and sucrose solution preference by rats treated with low doses of delta9-tetrahydrocannabinol. Behav. Biol. 20 (1977) 104-110
20. Brugman S., Clegg D.J., Woods S.C., and Seeley R.J. Combined blockade of both micro- and kappa-opioid receptors prevents the acute orexigenic action of Agouti-related protein. Endocrinology 143 (2002) 4265-4270
21. Bruning J.C., Gautam D., Burks D.J., Gillette J., Schubert M., Orban P.C., Klein R., Krone W., Muller-Wieland D., and Kahn C.R. Role of brain insulin receptor in control of body weight and reproduction. Science 289 (2000) 2122-2125
22. Canli T., Cook R.G., and Miczek K.A. Opiate antagonists enhance the working memory of rats in the radial maze. Pharmacol. Biochem. Behav. 36 (1990) 521-525
23. Castane P., Robledo A., Matifas B.L., and Kieffer R. Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. Eur. J. Neurosci. 17 (2003) 155-159
24. Cesselin F. Opioid and anti-opioid peptides. Fundam. Clin. Pharmacol. 9 (1995) 409-433
25. Chen R.Z., Huang R.C., Shen C.P., MacNeil D.J., and Fong T.M. Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice. Brain Res. 999 (2004) 227-230
26. Chou T.C., Lee C.E., Lu J., Elmquist J.K., Hara J., Willie J.T., Beuckmann C.T., Chemelli R.M., Sakurai T., Yanagisawa M., Saper C.B., and Scammell T.E. Orexin (hypocretin) neurons contain dynorphin. J. Neurosci. 21 (2001) RC168
27. Clegg D.J., Air E.L., Woods S.C., and Seeley R.J. Eating elicited by orexin-A, but not melanin-concentrating hormone, is opioid mediated. Endocrinology 143 (2002) 2995-3000
28. Cleland J.G., Ghosh J., Freemantle N., Kaye G.C., Nasir M., Clark A.L., and Coletta A.P. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur. J. Heart Fail. 6 (2004) 501-518
29. Cohen C., Perrault G., Voltz C., Steinberg R., and Soubrie P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav. Pharmacol. 13 (2002) 451-463
30. Colantuoni C., Schwenker J., McCarthy J., Rada P., Ladenheim B., Cadet J.L., Schwartz G.J., Moran T.H., and Hoebel B.G. Excessive sugar intake alters binding to dopamine and mu-opioid receptors in the brain. NeuroReport 12 (2001) 3549-3552
31. Colombo G., Serra S., Vacca G., Carai M.A., and Gessa G.L. Endocannabinoid system and alcohol addiction: pharmacological studies. Pharmacol. Biochem. Behav. 81 (2005) 369-380
32. Corchero J., Fuentes J.A., and Manzanares J. Delta 9-tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus. Eur. J. Pharmacol. 323 (1997) 193-195
33. Corchero J., Avila M.A., Fuentes J.A., and Manzanares J. Delta-9-tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat. Life Sci. 61 (1997) PL39-PL43
34. Cota D., and Woods S.C. The role of the endocannabinoid system in the regulation of energy homeostasis. Curr. Opin. Endocr. Diab. 12 (2005) 338-351
35. Cota D., Marsicano G., Lutz B., Vicennati V., Stalla G.K., Pasquali R., and Pagotto U. The endogenous cannabinoid system as a modulator of food intake. Int. J. Obes. Relat. Metab. Disord. 27 (2003) 289-301
36. Cota D., Marsicano G., Tschöp M., Grubler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thone-Reineke C., Ortmann S., Tomassoni F., Cervino C., Nisoli E., Linthorst A.C., Pasquali R., Lutz B., Stalla G.K., and Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112 (2003) 423-431
37. Cowley M.A., Smith R.G., Diano S., Tschop M., Pronchuk N., Grove K.L., Strasburger C.J., Bidlingmaier M., Esterman M., Heiman M.L., Garcia-Segura L.M., Nillni E.A., Mendez P., Low M.J., Sotonyi P., Friedman J.M., Liu H., Pinto S., Colmers W.F., Cone R.D., and Horvath T.L. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37 (2003) 649-661
38. Davis C., and Claridge G. The eating disorders as addiction: a psychobiological perspective. Addict. Behav. 23 (1998) 463-475
39. Davis C., Strachan S., and Berkson M. Sensitivity to reward: implications for overeating and overweight. Appetite 42 (2004) 131-138
40. de Lago E., Petrosino S., Valenti M., Morera E., Ortega-Gutierrez S., Fernandez-Ruiz J., and Di Marzo V. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochem. Pharmacol. 70 (2005) 446-452
41. Delamater A.R., Sclafani A., and Bodnar R.J. Pharmacology of sucrose-reinforced place-preference conditioning: effects of naltrexone. Pharmacol. Biochem. Behav. 65 (2000) 697-704
42. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
43. De Vries T.J., and Schoffelmeer A.N. Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol. Sci. 26 (2005) 420-426
44. De Vries T.J., de Vries W., Janssen M.C., and Schoffelmeer A.N. Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A. Behav. Brain Res. 161 (2005) 164-168
45. Di S., Malcher-Lopes R., and Halmos K.C. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J. Neurosci. 23 (2003) 4850-4857
46. Di Marzo V. 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim. Biophys. Acta 1392 (1998) 153-175
47. Di Marzo V., and Matias I. Endocannabinoid control of food intake and energy balance. Nat. Neurosci. 8 (2005) 85-589
48. Di Marzo V., Melck D., Bisogno T., and De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21 (1998) 521-528
49. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., and Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
50. Di Marzo V., De Petrocellis L., Fezza F., Ligresti A., and Bisogno T. Anandamide receptors. Prostaglandins, Leukotrienes Essent. Fatty Acids 66 (2002) 377-391
51. Dixon R., Howes J., Gentile J., Hsu H.B., Hsiao J., Garg D., Weidler D., Meyer M., and Tuttle R. Nalmefene: intravenous safety and kinetics of a new opioid antagonist. Clin. Pharmacol. Ther. 39 (1986) 49-53
52. Dortch-Carnes J., and Potter D.E. Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties. CNS Drug Rev. 11 (2005) 195-212
53. Fezza F., Bisogno T., Minassi A., Appendino G., Mechoulam R., and Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett. 513 (2002) 294-298
54. Flier J.S. Obesity wars: molecular progress confronts an expanding epidemic. Cell 116 (2004) 337-350
55. Freund T.F., Katona I., and Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83 (2003) 1017-1066
56. Frisch A., Laufer N., Danziger Y., Michaelovsky E., Leor S., Carel C., Stein D., Fenig S., Mimouni M., Apter A., and Weizman A. Association of anorexia nervosa with the high activity allele of the COMT gene: a family-based study in Israeli patients. Mol. Psychiatry 6 (2001) 243-245
57. Gallate J.E., Saharov T., Mallet P.E., and McGregor I.S. Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. Eur. J. Pharmacol. 370 (1999) 233-240
58. Garcia de Yebenes E., Li S., Fournier A., St-Pierre S., and Pelletier G. Regulation of proopiomelanocortin gene expression by neuropeptide Y in the rat arcuate nucleus. Brain Res. 674 (1995) 112-116
59. Gardner E.L. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol. Biochem. Behav. 81 (2005) 263-284
60. Gatley S.J., Gifford A.N., Volkow N.D., Lan R., and Makriyannis A. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur. J. Pharmacol. 307 (1996) 331-338
61. Glass M.J., Billington C.J., and Levine A.S. Naltrexone administered to central nucleus of amygdala or PVN: neural dissociation of diet and energy. Am. J. Physiol.: Regul., Integr. Comp. Physiol. 279 (2000) R86-R92
62. Gonzalez S., Cascio M.G., Fernandez-Ruiz J., Fezza F., Di Marzo V., and Ramos J.A. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res. 954 (2002) 73-81
63. Grill H.J., and Kaplan J.M. The neuroanatomical axis for control of energy balance. Front. Neuroendocrinol. 1 (2002) 2-40
64. Gulati K., and Ray A. Effects of intrahypothalamic morphine and its interactions with oxytocin and vasopressin during food intake in rats. Brain Res. 690 (1995) 99-103
65. Gura T. Obesity drug pipeline not so fat. Science 299 (2003) 849-852
66. Hajos N., Ledent C., and Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106 (2001) 1-4
67. Halaas J.L., Gajiwala K.S., Maffei M., Cohen S.L., Chait B.T., Rabinowitz D., Lallone R.L., Burley S.K., and Friedman J.M. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269 (1995) 543-546
68. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., Kustanovich I., and Mechoulam R. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. 98 (2001) 3662-3665
69. Harrold J.A., Elliott J.C., King P.J., Widdowson P.S., and Williams G. Down-regulation of cannabinoid-1 (CB1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food?. Brain Res. 952 (2002) 232-238
70. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11 (1991) 563-583
71. Hermann H., Marsicano G., and Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109 (2002) 451-460
72. Hilairet S., Bouaboula M., Carriere D., Le Fur G., and Casellas P. Hypersensitization of the orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J. Biol. Chem. 278 (2003) 23731-23737
73. Hill J.O., Wyatt H.R., Reed G.W., and Peters J.C. Obesity and the environment: where do we go from here?. Science 299 (2003) 853-855
74. Hillard C.J., Manna S., Greenberg M.J., Di Camelli R., Ross R.A., Stevenson L.A., Murphy V., Pertwee R.G., and Campbell W.B. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther. 289 (1999) 1427-1433
75. Horvath T.L. Endocannabinoids and the regulation of body fat: the smoke is clearing. J. Clin. Invest. 112 (2003) 323-326
76. Horvath T.L., and Diano S. The floating blueprint of hypothalamic feeding circuits. Nat. Rev., Neurosci. 5 (2004) 662-667
77. Horvath T.L., Diano S., Sotonyi P., Heiman M., and Tschop M. Minireview: ghrelin and the regulation of energy balance-a hypothalamic perspective. Endocrinology 142 (2001) 4163-4169
78. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. International union of Pharmacology: XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002) 161-202
79. Huang S.M., Bisogno T., Trevisani M., Al-Hayani A., De Petrocellis L., Fezza F., Tognetto M., Petros T.J., Krey J.F., Chu C.J., Miller J.D., Davies S.N., Geppetti P., Walker J.M., and Di Marzo V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. 99 (2002) 8400-8405
80. Huszar D., Lynch C.A., Fairchild-Huntress V., Dunmore J.H., Fang Q., Berkemeier L.R., Gu W., Kesterson R.A., Boston B.A., Cone R.D., Smith F.J., Campfield L.A., Burn P., and Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88 (1997) 131-141
81. Jamshidi N., and Taylor D.A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br. J. Pharmacol. 134 (2001) 1151-1154
82. Kalra S.P., Dube M.G., Pu S., Xu B., Horvath T.L., and Kalra P.S. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev. 20 (1999) 68-100
83. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Calignano A., Giustino A., Tattoli M., Palmery M., Cuomo V., and Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9 (2003) 76-81
84. Kaye W.H., Berrettini W.H., Gwirtsman H.E., Chretien M., Gold P.W., George D.T., Jimerson D.C., and Ebert M.H. Reduced cerebrospinal fluid levels of immunoreactive pro-opiomelanocortin related peptides (including beta-endorphin) in anorexia nervosa. Life Sci. 41 (1987) 2147-2155
85. Kelley A.E. Ventral striatal control of appetitive motivation: role in ingestive behavior and reward-related learning. Neurosci. Biobehav. Rev. 27 (2004) 765-776
86. Kelley A.E., Bakshi V.P., Haber S.N., Steininger T.L., Will M.J., and Zhang M. Opioid modulation of taste hedonics within the ventral striatum. Physiol. Behav. 76 (2002) 365-377
87. Kieffer B.L., Befort K., Gaveriaux-Ruff C., and Hirth C.G. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci. 89 (1992) 12048-12052
88. Killgore W.D., Young A.D., Femia L.A., Bogorodzki P., Rogowska J., and Yurgelun-Todd D.A. Cortical and limbic activation during viewing of high- versus low-calorie foods. NeuroImage 19 (2003) 1381-1394
89. Kirkham T.C., and Blundell J.E. Dual action of naloxone on feeding revealed by behavioral analysis: separate effects on initiation and termination of eating. Appetite 5 (1984) 45-52
90. Kirkham T.C., and Williams C.M. Endogenous cannabinoids and appetite. Nutr. Res. Rev. 14 (2001) 65-86
91. Kirkham T.C., and Williams C.M. Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology 153 (2001) 267-270
92. Kirkham T.C., Williams C.M., Fezza F., and Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. 136 (2002) 550-557
93. Kotz C.M., Grace M.K., Briggs J., Levine A.S., and Billington C.J. Effects of opioid antagonists naloxone and naltrexone on neuropeptide Y-induced feeding and brown fat thermogenesis in the rat. Neural site of action. J. Clin. Invest. 96 (1995) 163-170
94. Kotz C.M., Grace M.K., Briggs J.E., Billington C.J., and Levine A.S. Naltrexone induces arcuate nucleus neuropeptide Y gene expression in the rat. Am. J. Physiol. 271 (1996) R289-R294
95. Lan R., Gatley J., Lu Q., Fan P., Fernando S.R., Volkow N.D., Pertwee R., and Makriyannis A. Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. AAPS Pharm. Sci. 1 (1999) E4
96. Law P.Y., and Loh H.H. Regulation of opioid receptor activities. J. Pharmacol. Exp. Ther. 289 (1999) 607-624
97. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., Bohme G.A., Imperato A., Pedrazzini T., Roques B.P., Vassart G., Fratta W., and Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283 (1999) 401-404
98. Levine A.S., and Billington C.J. Opioids as agents of reward-related feeding: a consideration of the evidence. Physiol. Behav. 82 (2004) 57-61
99. Le Foll B., and Goldberg S.R. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J. Pharmacol. Exp. Ther. 312 (2005) 875-883
100. Levine A.S., Murray S.S., Kneip J., Grace M., and Morley J.E. Flavor enhances the antidipsogenic effect of naloxone. Physiol. Behav. 28 (1982) 23-25
101. Levine A.S., Grace M.K., Cleary J.P., and Billington C.J. Naltrexone infusion inhibits the development of preference for a high-sucrose diet. Am. J. Physiol.: Regul., Integr. Comp. Physiol. 283 (2002) R1149-R1154
102. Levine A.S., Olszewski P.K., Mullett M.A., Pomonis J.D., Grace M.K., Kotz C.M., and Billington C.J. Intra-amygdalar injection of DAMGO: effects on c-Fos levels in brain sites associated with feeding behavior. Brain Res. 1015 (2004) 9-14
103. Lichtman A.H., Leung D., Shelton C.C., Saghatelian A., Hardouin C., Boger D.L., and Cravatt B.F. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J. Pharmacol. Exp. Ther. 311 (2004) 441-448
104. Licko V. Overview of human pharmacokinetics of naltrexone. NIDA Res. Monogr. 28 (1981) 161-171
105. Lynch W.C. Opiate blockade inhibits saccharin intake and blocks normal preference acquisition. Pharmacol. Biochem. Behav. 24 (1986) 833-836
106. MacDonald A.F., Billington C.J., and Levine A.S. Alterations in food intake by opioid and dopamine signaling pathways between the ventral tegmental area and the shell of the nucleus accumbens. Brain Res. 1018 (2004) 78-85
107. Mansour A., Fox C.A., Akil H., and Watson S.J. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18 (1995) 22-29
108. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., and Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci. 20 (1999) 287-294
109. Marks-Kaufman R., Balmagiya T., and Gross E. Modifications in food intake and energy metabolism in rats as a function of chronic naltrexone infusions. Pharmacol. Biochem. Behav. 20 (1984) 911-916
110. Marsicano G., and Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur. J. Neurosci. 11 (1999) 4213-4225
111. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
112. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., Pertweee R.G., Griffine G., Bayewitchf M., Bargf J., and Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50 (1995) 83-90
113. Mercer M.E., and Holder M.D. Food cravings, endogenous opioid peptides, and food intake: a review. Appetite 29 (1997) 325-352
114. Meunier J.C. Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. Eur. J. Pharmacol. 340 (1997) 1-15
115. Monteleone P., Matias I., Martiadis V., De Petrocellis L., Maj M., and Di Marzo V. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 30 (2005) 1216-1221
116. Mouledous L., Topham C.M., Moisand C., Mollereau C., and Meunier J.C. Functional inactivation of the nociceptin receptor by alanine substitution of glutamine 286 at the C terminus of transmembrane segment VI: evidence from a site-directed mutagenesis study of the ORL1 receptor transmembrane-binding domain. Mol. Pharmacol. 57 (2000) 495-502
117. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
118. Navarro M., Carrera M.R., Fratta W., Valverde O., Cossu G., Fattore L., Chowen J.A., Gomez R., del Arco I., Villanua M.A., Maldonado R., Koob G.F., and Rodriguez de Fonseca F. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J. Neurosci. 21 (2001) 5344-5350
119. Noble E.P. Polymorphisms of the D2 dopamine receptor gene and alcoholism and other substance use disorders. Alcohol Alcohol., Suppl. 2 (1994) 35-43
120. Obici S., and Rossetti L. Minireview: nutrient sensing and the regulation of insulin action and energy balance. Endocrinology 144 (2003) 5172-5178
121. O'Hare E., Cleary J.P., Bartz P.J., Weldon D.T., Billington C.J., and Levine A.S. Naloxone administration following operant training of sucrose/water discrimination in the rat. Psychopharmacology 129 (1997) 289-294
122. Oka S., Tsuchie A., Tokumura A., Muramatsu M., Suhara Y., Takayama H., Waku K., and Sugiura T. Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J. Neurochem. 85 (2003) 1374-1381
123. Okada Y., Tsuda Y., Bryant S.D., and Lazarus L.H. Endomorphins and related opioid peptides. Vitam. Horm. 65 (2002) 257-279
124. Olive M.F., Koenig H.N., Nannini M.A., and Hodge C.W. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. J. Neurosci. 21 (2001) RC184
125. Olszewski P.K., and Levine A.S. Minireview: characterization of influence of central nociceptin/orphanin FQ on consummatory behavior. Endocrinology 145 (2004) 2627-2632
126. Olszewski P.K., Grace M.K., Billington C.J., and Levine A.S. The effect of [Phe(1)psi(CH(2)-NH)Gly(2)]-nociceptin(1-13)NH(2) on feeding and c-Fos immunoreactivity in selected brain sites. Brain Res. 876 (2000) 95-102
127. O'Rahilly S., Farooqi I.S., Yeo G.S., and Challis B.G. Minireview: human obesity-lessons from monogenic disorders. Endocrinology 144 (2003) 3757-3764
128. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Batkai S., Harvey-White J., Mackie K., Offertaler L., Wang L., and Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115 (2005) 1298-1305
129. Parker L.A., Maier S., Rennie M., and Crebolder J. Morphine- and naltrexone-induced modification of palatability: analysis by the taste reactivity test. Behav. Neurosci. 106 (1992) 999-1010
130. Pau K.Y., Kaynard A.H., Hess D.L., and Spies H.G. Effects of neuropeptide Y on the in vitro release of gonadotropin-releasing hormone, luteinizing hormone, and beta-endorphin and pituitary responsiveness to gonadotropin-releasing hormone in female macaques. Neuroendocrinology 53 (1991) 396-403
131. Pert C.B., Kuhar M.J., and Snyder S.H. Opiate receptor: autoradiographic localization in rat brain. Proc. Natl. Acad. Sci. 73 (1976) 3729-3733
132. Phillips A.G., and Nikaido R.S. Disruption of brain stimulation-induced feeding by dopamine receptor blockade. Nature 258 (1975) 750-751
133. Piomelli D. The molecular logic of endocannabinoid sygnalling. Nat. Rev., Neurosci. 4 (2003) 873-884
134. Pittman Q.J., Hatton J.D., and Bloom F.E. Morphine and opioid peptides reduce paraventricular neuronal activity: studies on the rat hypothalamic slice preparation. Proc. Natl. Acad. Sci. U. S. A. 77 (1980) 5527-5531
135. Pommier B., Beslot F., Simon A., Pophillat M., Matsui T., Dauge V., Roques B.P., and Noble F. Deletion of CCK2 receptor in mice results in an upregulation of the endogenous opioid system. J. Neurosci. 22 (2002) 2005-2011
136. Poncelet M., Maruani J., Calassi R., and Soubrie P. Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci. Lett. 343 (2003) 216-218
137. Porter A.C., and Felder C.C. The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol. Ther. 90 (2001) 45-60
138. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., Nomikos G.G., Carter P., Bymaster F.P., Leese A.B., and Felder C.C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 301 (2002) 1020-1024
139. Ragnauth A., Znamensky V., Moroz M., and Bodnar R.J. Analysis of dopamine receptor antagonism upon feeding elicited by mu and delta opioid agonists in the shell region of the nucleus accumbens. Brain Res. 877 (2000) 65-72
140. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma Jr. F.J., and Civelli O. Orphanin FQ: a neuropeptide that activates an opioid like G protein-coupled receptor. Science 270 (1995) 792-794
141. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere J.C., and Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350 (1994) 240-244
142. Rolls E.T. Taste, olfactory, and food texture processing in the brain, and the control of food intake. Physiol. Behav. 85 (2005) 45-56
143. Rowland N.E., Mukherjee M., and Robertson K. Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology (Berlin) 159 (2001) 111-116
144. Saito Y., Cheng M., Leslie F.M., and Civelli O. Expression of the melanin-concentrating hormone (MCH) receptor mRNA in the rat brain. J. Comp. Neurol. 435 (2001) 26-40
145. Saper C.B., Chou T.C., and Elmquist J.K. The need to feed: homeostatic and hedonic control of eating. Neuron 36 (2002) 199-211
146. Schlicker E., and Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22 (2001) 565-572
147. Schwartz M.W., Seeley R.J., Campfield L.A., Burn P., and Baskin D.G. Identification of targets of leptin action in rat hypothalamus. J. Clin. Invest. 98 (1996) 1101-1106
148. Seeley R.J., and Woods S.C. Monitoring of stored and available fuel by the CNS: implications for obesity. Nat. Rev., Neurosci. 4 (2003) 901-909
149. Seeley R.J., Yagaloff K.A., Fisher S.L., Burn P., Thiele T.E., van Dijk G., Baskin D.G., and Schwartz M.W. Melanocortin receptors in leptin effects. Nature 390 (1997) 349
150. Shide D.J., and Blass E.M. Opioid mediation of odor preferences induced by sugar and fat in 6-day-old rats. Physiol. Behav. 50 (1991) 961-966
151. Siegfried Z., Kanyas K., Latzer Y., Karni O., Bloch M., Lerer B., and Berry E.M. Association study of cannabinoid receptor gene (CNR1) alleles and anorexia nervosa: differences between restricting and binging/purging subtypes. Am. J. Med. Genet., Part B Neuropsychiatr. Genet. 125 (2004) 126-130
152. Simansky K.J. Serotonergic control of the organization of feeding and satiety. Behav. Brain Res. 73 (1996) 37-42
153. Singh M.E., Verty A.N., Price I., McGregor I.S., and Mallet P.E. Modulation of morphine-induced Fos-immunoreactivity by the cannabinoid receptor antagonist SR 141716. Neuropharmacology 47 (2004) 1157-1169
154. Sipe J.C., Chiang K., Gerber A.L., Beutler E., and Cravatt B.F. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 8394-8399
155. Sipe J.C., Waalen J., Gerber A., and Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int. J. Obes. Relat. Metab. Disord. 29 (2005) 755-759
156. Smith G.P. The direct and indirect controls of meal size. Neurosci. Biobehav. Rev. 20 (1996) 41-46
157. Spanagel R., and Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci. 22 (1999) 521-527
158. Stratford T.R., Holahan M.R., and Kelley A.E. Injections of nociceptin into nucleus accumbens shell or ventromedial hypothalamic nucleus increase food intake. NeuroReport 8 (1997) 423-426
159. Sugiura T., Kodaka T., Nakane S., Miyashita T., Kondo S., Suhara Y., Takayama H., Waku K., Seki C., Baba N., and Ishima Y. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J. Biol. Chem. 274 (1999) 2794-2801
160. Sugiura T., Kondo S., Kishimoto S., Miyashita T., Nakane S., Kodaka T., Suhara Y., Takayama H., and Waku K. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem. 275 (2000) 605-612
161. Sugiura T., Kobayashi Y., Oka S., and Waku K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins, Leukotrienes Essent. Fatty Acids 66 (2002) 173-192
162. Sweet D.C., Levine A.S., and Kotz C.M. Functional opioid pathways are necessary for hypocretin-1 (orexin-A)-induced feeding. Peptides 25 (2004) 307-314
163. Szczypka M.S., Rainey M.A., Kim D.S., Alaynick W.A., Marck B.T., Matsumoto A.M., and Palmiter R.D. Feeding behavior in dopamine-deficient mice. Proc. Natl. Acad. Sci. 96 (1999) 12138-12143
164. Szczypka M.S., Kwok K., Brot M.D., Marck B.T., Matsumoto A.M., Donahue B.A., and Palmiter R.D. Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. Neuron 30 (2001) 819-828
165. Tanda G., and Goldberg S.R. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms-a review of recent preclinical data. Psychopharmacology 169 (2003) 115-134
166. Tartaglia L.A., Dembski M., Weng X., Deng N., Culpepper J., Devos R., Richards G.J., Campfield L.A., Clark F.T., Deeds J., Muir C., Sanker S., Moriarty A., Moore K.J., Smutko J.S., Mays G.G., Woolf E.A., Monroe C.A., and Tepper R.I. OB-RIdentification and expression cloning of a leptin receptor. Cell 83 (1995) 1263-1271
167. Trojniar W., and Wise R.A. Facilitatory effect of delta 9-tetrahydrocannabinol on hypothalamically induced feeding. Psychopharmacology (Berlin) 103 (1991) 172-176
168. Tschop M., Smiley D.L., and Heiman M.L. Ghrelin induces adiposity in rodents. Nature 407 (2000) 908-913
169. Valverde O., Maldonado R., Valjent E., Zimmer A.M., and Zimmer A. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J. Neurosci. 20 (2000) 9284-9289
170. Van Gaal L.F., Rissanen A., Scheen A., Ziegler O., and Rossner S. Effect of rimonabant on weight reduction and cardiovascular risk. Lancet 366 (2005) 369-370
171. Vela G., Ruiz-Gayo M., and Fuentes J.A. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 34 (1995) 665-668
172. Verty A.N., Singh M.E., McGregor I.S., and Mallet P.E. The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine. Psychopharmacology (Berlin) 168 (2003) 314-323
173. Vigano D., Cascio M.G., Rubino T., Fezza F., Vaccani A., Di Marzo V., and Parolaro D. Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. Neuropsychopharmacology 28 (2003) 1160-1167
174. Vigano D., Valenti M., Cascio M.G., Di Marzo V., Parolaro D., and Rubino T. Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine. Eur. J. Neurosci. 20 (2004) 1849-1857
175. Volkow N.D., and Wise R.A. How can drug addiction help us understand obesity?. Nat. Neurosci. 5 (2005) 555-560
176. Volkow N.D., Wang G.J., Fowler J.S., Thanos P.P., Logan J., Gatley S.J., Gifford A., Ding Y.S., Wong C., and Pappas N. Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse (2002) 79-82
177. Volkow N.D., Wang G.J., Maynard L., Jayne M., Fowler J.S., Zhu W., Logan J., Gatley S.J., Ding Y.S., Wong C., and Pappas N. Brain dopamine is associated with eating behaviors in humans. Int. J. Eat. Disord. 33 (2003) 136-142
178. Waldhoer M., Bartlett S.E., and Whistler J.L. Opioid receptors. Annu. Rev. Biochem. 73 (2004) 953-990
179. Wang G.J., Volkow N.D., Logan J., Pappas N.R., Wong C.T., Zhu W., Netusil N., and Fowler J.S. Brain dopamine and obesity. Lancet 357 (2001) 354-357
180. Welch C.C., Kim E.M., Grace M.K., Billington C.J., and Levine A.S. Palatability-induced hyperphagia increases hypothalamic dynorphin peptide and mRNA levels. Brain Res. 721 (1996) 126-131
181. Wiesenfeld-Hallin Z., de Arauja Lucas G., Alster P., Xu X.J., and Hokfelt T. Cholecystokinin/opioid interactions. Brain Res. 848 (1999) 78-89
182. Williams C.M., and Kirkham T.C. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berlin) 143 (1999) 315-317
183. 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol. Biochem. Behav. 71 (2002) 341-348
184. Williams C.M., Rogers P.J., and Kirkham T.C. Hyperphagia in pre-fed rats following oral delta9-THC. Physiol. Behav. 65 (1998) 343-346
185. Woods S.C. Gastrointestinal satiety signals: I. An overview of gastrointestinal signals that influence food intake. Am. J. Physiol.: Gastrointest. Liver Physiol. 286 (2004) G7-G13
186. Woods S.C., Lotter E.C., McKay L.D., and Porte Jr. D. Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature 282 (1979) 503-505
187. Yamaguchi T., Hagiwara Y., Tanaka H., Sugiura T., Waku K., Shoyama Y., Watanabe S., and Yamamoto T. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res. 909 (2001) 121-126
188. Yao L., Fan P., Jiang Z., Mailliard W.S., Gordon A.S., and Diamond I. Addicting drugs utilize a synergistic molecular mechanism in common requiring adenosine and Gi-βγ dimers. Proc. Natl. Acad. Sci. 100 (2003) 14379-14384
189. Yeomans M.R., and Gray R.W. Opioid peptides and the control of human ingestive behaviour. Neurosci. Biobehav. Rev. 26 (2002) 713-728
190. Yirmiya R., Lieblich I., and Liebeskind J.C. Reduced saccharin preference in CXBK (opioid receptor-deficient) mice. Brain Res. 438 (1988) 339-342
191. Yu W.Z., Sclafani A., Delamater A.R., and Bodnar R.J. Pharmacology of flavor preference conditioning in sham-feeding rats: effects of naltrexone. Pharmacol. Biochem. Behav. 64 (1999) 573-584
192. Zadina J.E., Hackler L., Ge L.J., and Kastin A.J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386 (1997) 499-502
193. Zhang M., and Kelley A.E. Intake of saccharin, salt, and ethanol solutions is increased by infusion of a mu opioid agonist into the nucleus accumbens. Psychopharmacology (Berlin) 159 (2002) 415-423
194. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432
195. Zhang M., Gosnell B.A., and Kelley A.E. Intake of high-fat food is selectively enhanced by mu opioid receptor stimulation within the nucleus accumbens. J. Pharmacol. Exp. Ther. 285 (1998) 908-914
196. Zhu H., Brodsky M., Gorman A.L., and Inturrisi C.E. Region-specific changes in NMDA receptor mRNA induced by chronic morphine treatment are prevented by the co-administration of the competitive NMDA receptor antagonist LY274614. Brain Res. Mol. Brain Res. 114 (2003) 154-162